Get the Stockscreener App
11.71
1.74%
0.20
After Hours:
11.71
Arcutis Biotherapeutics Inc stock is traded at $11.71, with a volume of 1.69M.
It is up +1.74% in the last 24 hours and up +33.83% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$11.51
Open:
$11.6
24h Volume:
1.69M
Relative Volume:
0.89
Market Cap:
$1.35B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-2.1137
EPS:
-5.54
Net Cash Flow:
$-247.49M
1W Performance:
+15.03%
1M Performance:
+33.83%
6M Performance:
+27.84%
1Y Performance:
+497.45%
1-Day Range:
$11.38
$11.88
1-Week Range:
$10.03
$11.88
52-Week Range:
$1.76
$13.17
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
11.71 | 1.35B | 59.61M | -262.14M | -247.49M | -5.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
(ARQT) Investment Analysis - Stock Traders Daily
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Yahoo Finance
Rubric Capital Management LP Has $101.99 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump - Simply Wall St
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Arcutis Biotherapeutics SVP sells shares worth $712,620 - Investing.com
Arcutis Biotherapeutics SVP sells shares worth $712,620 By Investing.com - Investing.com UK
Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com Australia
Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com
Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com
Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times
Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan
GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance
Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India
Trend Tracker for (ARQT) - Stock Traders Daily
Arcutis biotherapeutics CMO sells $134,092 in stock - Investing.com India
Arcutis Biotherapeutics director sells $86,541 in stock - Investing.com
Arcutis biotherapeutics CMO sells $134,092 in stock By Investing.com - Investing.com UK
Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result - GuruFocus.com
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):